eliminate the redundancy of the commonly used 27-item pain tool, the Barriers Questionnaire (BQ-27); retain its theoretical domains; and maintain its psychometric properties in a new shortened version. b Method: The BQ-27 was reduced to 13 items using data from 259 patients with cancer by selecting the single item from each domain with the highest frequency of endorsement and including all of the items in the side effects subscale. We tested reliability of the BQ-13 using data from additional studies (n = 221 and 166) and used analysis of covariance (n = 221) to determine instrument sensitivity. b Results: Confirmatory factor analysis revealed that the BQ-13 contained two constructs: pain management and side effects. The BQ-13 demonstrated internal consistency as a total scale (! = .73) and stability via 4-week testYretest reliability. In addition, the BQ-13 was sensitive, F(1,218) = 7.7, p = .006, to effects of a tailored multimedia educational intervention. b Discussion: The BQ-13 retained theoretical constructs, eliminated redundant items likely to contribute to floor effects, maintained adequate internal consistency and stability reliability, and had sensitivity to intervention effects. Ward et al., 1993) has eight domains and is a valid and reliable measure of patients' beliefs about pain and analgesics. However, it is plagued by redundant items and floor effects. Two shortened versions (Ward, Carlson-Dakes, Hughes, Kwekkeboom, & Donovan, 1998; Wells, Johnson, & Wujcik, 1998) overcame the tool's redundancy; however, the sensitivity of the shorten tools was not reported (Ward et al., 1998; Wells et al., 1998) until recently (Ward, Wang, Serlin, Peterson, & Murray, 2009 ). The purposes of this series of research studies were to eliminate the redundancy of the BQ items, reduce the floor effects, retain the domain concepts, and maintain adequate psychometric properties of a new shortened version of the BQ.
Literature Review Using Johnson's self-regulation theory (Johnson, Fieler, Wlasowicz, Mitchell, & Jones, 1997) , Ward et al. (1993) asserted that patient-held beliefs are critical to achieving optimal pain management and demonstrated that many patients held beliefs that were inconsistent with known facts about pain. Patients' misconceived beliefs, such as that pain is an uncontrollable side effect of disease or that use of pain medications leads to addiction, may result in nonadherence to prescribed medication and poorly controlled pain (Ward et al., 1993; Wells et al., 1998) . Few tools existed to measure patients' beliefs regarding pain and analgesics until Ward et al. developed the 27-item BQ. Since then, researchers (Gunnarsdottir, Serlin, & Ward, 2005; Ward, Donovan, Owen, Grosen, & Serlin, 2000; Ward et al., 1993; Ward & Hernandez, 1994) and clinicians (Glajchen, 2001 ) have relied on the BQ-27 to guide pain investigations, despite how taxing the redundant items may have been to patients.
Specifically, the 27 BQ items measure patient-held beliefs regarding pain and pain medication in the following eight domains: (a) fear of addiction, (b) medication tolerance, (c)
Nursing Research March/April 2010 Vol 59, No 2 fatalism, (d) desire to be a good patient, (e) disease progression, (f) fear of injections, (g) distracting the provider, and (h) medication side effects. Patients are asked to respond to each item measured with a Likert scale (0 = do not agree at all, 5 = agree very much). Mean T SD scores for the total scale are typically low: 1.65 T 0.81 in 270 outpatient oncology patients (Ward et al., 1993 ); 1.94 T 0.85 and 1.80 T 0.61 in 35 hospice patients and their caregivers, respectively (Ward, Berry, & Misiewicz, 1996) ; and 1.85 T 0.76 in 93 cancer and noncancer patients at Time 1 during a study evaluating stability of the tool and 1.72 T 0.85 (n = 56) at Time 2 (Ward & Gatwood, 1994) . These scores indicate the possibility that many patients did not endorse items, thereby providing a score of 0, which could contribute to a skewed distribution and floor effects of the instrument when it is used as an outcome variable.
The floor effects may help explain the inconsistent findings regarding the tool's sensitivity to intervention effects. The original BQ-27 was not sensitive to effects of an individualized intervention to overcome patient-related barriers to pain management in women with gynecological cancer (Ward et al., 2000) ; however, the small sample size (n = 43) may have been another contributor to the lack of sensitivity. Additional intervention studies using the original BQ-27 were not found in the literature. However, modified versions of the BQ-27, specifically the BQ-II (Gunnarsdottir, Donovan, Serlin, Voge, & Ward, 2002) and the BQ-17 (Wells et al., 1998) , were used in interventional studies. In the BQ-II, investigators replaced the fear of injection and the disease progression subscales with two new subscales: fear that pain medications impair the immune system and pain medication interferes with illness monitoring. The BQ-II was sensitive to the effects of a representational intervention to decrease pain in 170 patients with metastatic cancer (Ward et al., 2008) . Wells et al. (1998) deleted the fear of injections subscale and items with less than .70 interitem and intertotal correlations. The resulting BQ-17 demonstrated mixed sensitivity results, showing improvement in BQ scores immediately after an educational intervention and significant results only in the medication side effect subscale after an intervention booster 4 to 6 weeks later in a group of 150 and 75 registered nurses, respectively (Vallerand, Riley-Doucet, Hasenau, & Templin, 2004) . A 24-item BQ was sensitive to a videobased pain management intervention in 93 oncology clinic patients (Syrjala et al., 2008) , but the investigators did not report which items were deleted or retained. Lin (2000) deleted the fear of injections subscale, added 4 additional items to the side effects subscale, and added two additional subscales: religious fatalism and the PRN subscale, which addresses the frequency of analgesic scheduling. Although the resulting 34-item BQ-Taiwan (Lin, 2000) is culturally sensitive, it poses even greater risk for respondent burden than does the original BQ-27. Furthermore, the BQ-Taiwan has not been tested for applicability in non-Chinese populations. Ward and colleagues (Ward et al., 1998 (Ward et al., , 2000 acknowledged that respondent burden was an issue with the BQ-27 and used an 8-item BQ, but they did not report the retained items. The American Pain Society [APS] Quality of Care Committee (1995) used expert panel and literature review to select 7 BQ items that they included in a patient outcome questionnaire (McNeill, Sherwood, Starck, & Thompson, 1998) . Table 1 lists the items that the various researchers used in their studies. The extensive interest in modifying the BQ-27 indicates that investigators have confidence in the tool but desire refinements to meet the specific needs of their studies.
Researchers have examined the validity of the BQ. Ward et al. (1993) used an expert panel to inform the content validity of the tool. Published literature was not found with evidence of a factor analysis to support the construct validity of the original 27-item BQ. However, Wells et al. (1998) , using factor analyses of the BQ-17 items, demonstrated two constructs that they labeled communicating with clinicians and concerns with analgesic use, and these constructs were consistent with the original conceptualizations of Ward et al. Significant relationships between BQ scores and variables such as pain severity scores (Ward & Hernandez, 1994) , hesitancy to report pain, and hesitancy to use analgesics (Ward & Gatwood, 1994) support the tool's convergent validity.
Evidence suggests that the BQ-27 is reliable, as demonstrated by its internal consistency and stability in testYretest conditions. Ward et al. (1993) reported a Cronbach's alpha of .89 for the original BQ-27. For the Spanish version of the tool, investigators reported an alpha of .82 (Ward & Hernandez, 1994) . Similarly, investigators (Ward et al., 1996) reported alpha values of .82 (n = 35 patients) and .90 (n = 35 caregivers) in their study of patient-related barriers to pain management in hospice settings. In addition, investigators (Ward & Gatwood, 1994) reported that the tool was stable after a 1-week interval, with a testYretest reliability coefficient of .90.
Evidence supports the conclusion that the BQ-27 is reliable and valid but also poses participant burden (Ward et al., 1998; Wells et al., 1998) . Although several reduceditem versions have been used, insufficient evidence is available to support their sensitivity, which is desirable when the tool is used as an outcome measure. The specific aims of this series of studies, which began before publication of either shortened BQ tool, were to use statistical and analytical approaches to create a shortened BQ tool, maintain the original's theoretical constructs, and determine the new tool's validity, internal consistency, stability, and sensitivity.
Methods
Design, Setting, and Sample In Table 2 , the study design, settings, and sample characteristics for all studies from which we analyzed data for this methods article are summarized. All participants (total N = 646) were unique and participated in only one study. Institutional board review approval and informed consent were received for all studies referenced in this article, including approval by the University of Illinois for ongoing analysis of deidentified data collected at the University of Washington. In summary, a secondary analysis was performed on data collected from Study A to reduce the number of items because patients in Study A complained about the redundant items and because missing data on repeated measures were a threat to study validity. Also, data were analyzed from Study A to evaluate the construct validity of the reduced 13-item tool (BQ-13). Subsequently, the BQ-13 was a component of two randomized clinical trials (Studies B and C), which q Pain intensity, M T SD (minimumYmaximum) Current pain 2.6 T 2.5 (0Y10) 2.0 T 2.2 (0Y10) 5.0 T 2.9 (0Y10) Least pain 0.8 T 0.7 (0Y4) 1.5 T 1.9 (0Y8) 3.9 T 2.9 (0Y10) Worst pain 3.0 T 1.3 (0Y5) 3.0 T 2.8 (0Y10) 6.8 T 2.6 (0Y10) facilitated examining its validity, reliability, and sensitivity. Study C was recently completed, and outcome analyses are in progress; it therefore contributed only baseline and internal consistency data to these analyses.
Procedures
Instrument Reduction In Study A, 259 patients completed a paper-and-pencil version of the BQ-27 upon entry into the study (Time 1) and 4 weeks later (Time 2). The BQ-27 was reduced by selecting from seven domains the single item with the greatest percentage of patient endorsement. This process was used because items with very low endorsement rates typically do not contribute to the psychometric properties of a tool and increase respondent burden (Streiner & Norman, 2003) . The 7 items selected by this process represented each of the original domains except side effects. All 6 items in the side effects domain were selected to facilitate tailoring interventions directed at analgesic side effects such as constipation, drowsiness, nausea, confusion, and embarrassment (Studies B and C). The 13 BQ items represented barriers reflecting pain management and side effects domains, as expected.
Validity To identify the best constructs represented by the BQ-13 items, two models were analyzed and compared for how well each fit the data. The first model with one factor was proposed to represent pain barriers and the second model with two factors to represent side effects barriers and pain management barriers. Confirmatory factor analyses (CFAs) were conducted using maximum likelihood estimation with AMOS 17.0 (SPSS Inc, Chicago, IL). Several fit indices were used to examine how well each of the proposed models fit the current data, including the chi-square goodness-of-fit statistic, the comparative fit index, the goodnessof-fit index, the adjusted goodness-of-fit index, and Akaike information criterion (AIC).
Reliability and Sensitivity Cronbach's alpha was used to evaluate the internal consistency of the BQ-27 and BQ-13 in our samples. Using Pearson correlations, the 4-week stability was determined for both versions only in the participants randomly assigned to the control group who had not had a study intervention between study entry and the 4-week repeat measurement point. With analysis of covariance (ANCOVA), controlling for Study B baseline values, we determined the sensitivity of the BQ-13 to the effects of a psychoeducational intervention.
Results

Instrument Reduction
In Study A, the frequency (n = 259) of items not endorsed (0 = meaning did not agree at all with the item) by the respondents at the baseline measure was calculated. Percentages ranged from 12% to 70%, with the fatalism domain having the largest percentage of nonendorsed items (answers of 0). As shown in Table 1 , 11 items were nonendorsed by at least 48% of the sample (n = 259). We used these data to select items for the reduced tool. The criteria for our selection of retained items included the following: (a) at least one item to represent each domain and each individual side effect, (b) item with the smallest percentage of 0 selected as the response, and (c) readability and clarity of retained item. Thirteen items met these criteria, and we named the tool BQ-13 (Table 1) . Table 1 lists the descriptive statistics from Study A at baseline for BQ-27 and BQ-13 scores. The BQ-27 (n = 259) mean scores ranged from 0.2 to 3.8, with an overall mean score of 1.6 T 0.7, and the BQ-13 scores were comparable, ranging from 0 to 4.0, with an overall mean score of 1.9 T 0.8. The mean domain scores of BQ-27 ranged from 0.92 T 0.96 to 2.5 T 1.4, and the single-item scores that represented each domain of the BQ-13 were similar, ranging from 1.1 T 1.4 to 2.7 T 1.9.
Construct Validity
Model 1 (One-Factor Model) The One-Factor Model was the base model to be compared with the model with more factors across the three different studies: Studies A, B, and C. The chi-square statistics indicated that the data from the studies did not provide an adequate fit of the data (Table 3) . However, chi-square is rarely used in isolation to determine the goodness of fit of a model because of sensitivity to sample size and external variables such as sample distribution. The fit indices also suggested that the One-Factor Model was not a good fit (Table 3) .
Model 2 (Two-Factor Model) In the Two-Factor Model, the chi-square statistics for each of the studies were significant (Table 3) ; however, the value of each study was considerably lower than the chi-square statistics from the One-Factor Model. Compared with those of the One-Factor Model, the fit indices values were high and much improved (Table 3 ). In addition, the ratio of chi-square and AIC of the Two-Factor Model was below the suggested criterion of 2.0 for an acceptable fit (Bollen, 1989) . The Two-Factor Model had higher fit indices and a substantially lower AIC value:chisquare ratio than that of the One-Factor Model. Thereby, the Two-Factor Model demonstrated a better representation of the BQ-13 data.
Reliability
The BQ-13 demonstrated acceptable internal consistency as a total scale and stability over time. The Cronbach's alpha values for Study A were .73 at baseline and .76 at 4 weeks after baseline ( Table 2) .
The Study B alpha values were .83 and .86 at baseline and 4 weeks after baseline, respectively. For Study C, the baseline alpha was .75. Table 4 lists the alpha values for the two subscales identified from the factor analysis for the baseline and 4-week measures in Study B. The side effects factor was highly reliable, with alpha values of .9. The internal consistency of the pain management factor (.66) was slightly lower than the desired .70. Table 4 also shows that the reliability indices are highly stable across the two measurement times. Removal of the two items with low loadings on the pain management factor either reduced or slightly improved the baseline alpha (BQ4 = .64, BQ7 = .69) and the 4-week alpha (BQ4 = .66, BQ7 = .66). Furthermore, the item-to-total-scale correlations were low but positive at baseline (BQ4 = .19, BQ7 = .32) and at 4-weeks (BQ4 = .27, BQ7 = .27).
In addition to acceptable internal consistency, the BQ-13 demonstrated stability via 4-week testYretest reliability, with coefficients of r = .59 for the control group (n = 133) in Study A and r = .74 for the control group (n = 106) in Study B. The 4-week Study B testYretest reliability for the Pain Management Factor 1 was .67, and that for the Side Effects Factor 2 was .68. Note. GFI = goodness-of-fit index; AGFI = adjusted goodness-of-fit index; CFI = comparative goodness-of-fit index; AIC =Akaike information criterion.
q 
Sensitivity
In Study B (Wilkie et al., n.d.) , the mean T SD BQ-13 scores were 1.7 T 1.0 for control (n = 106) and 1.9 T 0.9 for the experimental (n = 115) groups. We controlled for baseline BQ-13 scores and using ANCOVA demonstrated that the BQ-13 total score was sensitive, F(1,218) = 7.7, p = .006, to effects of a computerized intervention that was tailored to the patient's misconceptions about pain (PAINUCope; Wilkie et al., manuscript in preparation.) . Also tested were ANCOVA models using factor scores, and it was found that both factors (Pain Management Factor 1 with seven items, F(1,218) = 3.9, p = 0.049; Side Effects Factor 2 with six items, F(1,218) = 4.6, p = 0.034) were also significant, but the significance level was not as strong as the model with the BQ-13 total score. Because factor loadings for two items on the pain management factor (Factor 1) was low, a 5-item Pain Management model was tested also, but it was not significant, indicating that the two items did contribute to detection of group differences.
Discussion
Strong evidence was presented that the BQ-13 is valid, reliable, sensitive, and psychometrically equivalent to the BQ-27. The BQ-13 is less burdensome for participants and includes seven items that measure barriers related to pain management and six items specifically related to analgesic side effects. The internal consistency of the BQ-13 total scale is excellent, and the internal consistency of the two factor scores is excellent (analgesic side effects) to marginal (pain management). The BQ-13 4-week stability is marginally adequate for the total score and for the two factor scores. It is sensitive to a psychoeducational intervention with use of either total scale or factor scores, reduces potential for floor effects, and eliminates the redundancy of the BQ-27 and the respondent burden associated with the longer tool. In addition, the shorter tool maintained the conceptual framework underpinning the longer tool by including items from all eight domains. Confirmatory factor analysis was used to evaluate the construct validity of the BQ-13. When compared with exploratory factor analysis (EFA), CFA is a more advanced statistical computation that yields a higher degree of certainty regarding the construct validity of a tool (Streiner & Norman, 2003) . In addition, CFA reduces the error associated with EFA, although both methods are subject to sample biased variations (Costello & Osborne, 2005) . Last, CFA facilitates evaluating tools across a range of populations (Costello & Osborne, 2005) . The BQ-13 CFA results of two constructs were fairly consistent across our heterogeneous cancer samples and with findings from Wells et al. (1998) , who also identified two constructs in their EFA of the BQ-17. Furthermore, the factor structure of the BQ-13 is stable, as evidenced by analysis of data from the measures at baseline and 4 weeks later. The domains validated for all versions of the BQ-27 are widely supported by previous research. Numerous investigators (Anderson et al., 2000; Ward et al., 1993; Wilkie et al., 2001 ) have documented that patient beliefs mediate pain management. Factor analysis of the 13-item instrument yielded a single factor that contained the seven core domains of the BQ-27, as well as an additional construct (medication side effects) that may facilitate tailoring pain management interventions. The two items with low loadings on the pain management factor were retained because the Cronbach's alpha values were not improved by their removal, the item-to-total-scale correlations were positive, and it was thought that they represent important barriers to pain management. The BQ-13 retained construct validity, which is a foundational component of an effective research instrument.
The reliability of the BQ-13 is comparable with the reliability of the longer instrument. In her original work, Ward et al. (1993) reported an alpha of .89 (n = 270), and our BQ-27 results revealed similar alpha values (n = 259) at Time 1 and Time 2. The alpha values of the BQ-13 were higher in Study B and consistent in Studies A and C, with the alpha of .70 that Ward and colleagues reported for an 8-item BQ (Ward et al., 1998) and higher than the alpha of .62 for the short-form BQ-II (Ward et al., 2009 ). The lower alpha values are not surprising given the significant reduction in the number of items in the reduced tool (Streiner & Norman, 2003 ), yet they are higher than those that Ward et al. (2009) recently reported in a large sample and telephone delivery of the tool. In addition, results for the 4-week testYretest stability of the BQ-27 and BQ-13 in these studies indicate that reducing the BQ-27 to 13 items does not affect the reliability of the instrument.
Despite various methods employed to reduce BQ-27 items, there are many similarities and some differences in the items selected by the different investigative groups. The APS Quality of Care Committee (1995) used expert panel and literature review to select items from the BQ-27 for their outcome tool. Although such techniques are acceptable methods of tool reduction, expert panels may be plagued with varying degrees of subjectivity (Williams & Webb, 1994) . Alternatively, frequency endorsement may be a more empirically based process of tool reduction because the method may improve the discriminative power of the tool (Jadad et al., 1996) . Table 1 lists a comparison of the items in Ward's original BQ-27, the BQ-17, the items suggested by APS Quality of Care Committee, and the items retained for the BQ-13. Determining the superiority of the various reduceditem BQ tools requires additional research, which was not the focus of this series of studies.
In general, both the BQ-13 item scores and the total scale scores were slightly higher than the BQ-27 mean domain and total scale scores. The higher BQ-13 item scores can be attributed to the measurement of a single item that was often endorsed with a rating greater than 0, as opposed to the measurement of three items, some of which were rated 0 by many participants, to achieve a mean domain score for the BQ-27. This issue was particularly salient for the items representing the pain management factor because each of the original domains is now represented by a single item rather than the mean of three items. Furthermore, this property of higher scale scores is desirable as it reduces floor effects.
As with all research, there are limitations to this study. Two of the samples were 90% Caucasian, and one sample was 19% Caucasian. A more diverse sample may have produced different results, but similarities between findings of Study B and Study C suggest that validity and reliability findings were robust. Furthermore, other variables such as patient education level, type of cancer, and stage of disease may affect patients' perceptions, barriers, and pain experiences but have not been evaluated in this series of studies.
Conclusion
Research tools that effectively measure patient beliefs regarding pain and pain control can facilitate the development of interventions that mitigate misconceptions and promote improved pain control. However, lengthy investigative tools can place considerable burdens on patients and discourage patients from participating in research (McMillan & Weitzner, 2000) . Therefore, tools that effectively measure research constructs without needlessly taxing participants are essential to investigating pain barriers. The BQ-13 maintains empirically tested theoretical constructs, is concise, and is reliable, which likely will render the tool more amenable to research and clinical endeavors than will the original 27-item tool. Its comparability to other reduced-item barriers scales requires additional research. q
